1,442
Views
3
CrossRef citations to date
0
Altmetric
Case Reports

Aripiprozole-Induced Diplopia: A Case Report

Aripiprozole bağlı diplopi: Bir olgu sunumu

, , , M.D. &
Pages 353-356 | Received 15 Feb 2013, Accepted 03 Mar 2013, Published online: 08 Nov 2016
 

ABSTRACT

Diplopia is a condition that involves seeing double and impairs quality of life. Acute diplopia can be seen with some general medical drugs and psychotropic drugs. Aripiprazole is a new atypical antipsychotic agent; it has partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors. This paper reports development of diplopia, a rare adverse effect of psychotropic drugs, in a 24 year old patient with schizophreniform disorder following use of oral aripiprazole. Clinicians should keep in mind that diplopia may occur with aripiprazole treatment.

ÖZET

Diplopi çift görme olarak tanımlanan ve yaşam kalitesini bozan bir durumdur. Akut diplopi bazı genel tıbbi ilaçlar ve psikotrop ilaç kullanımında görülmektedir. Aripiprazol D2 ve 5-HT1A reseptörlerine parsiyel agonist ve 5-HT2A reseptörlerine antagonist aktivite gösteren atipik antipsikotik ajandır. Bu yazıda şizofreniform bozukluk tanısıyla takip edilen 24 yaşındaki bir hastada, oral aripiprazol kullanımını takiben ortaya çıkan, diplopi olgusu bildirilmektedir. Klinisyenler aripiprazol tedavisiyle diplopi ortaya çıkabileceğini akılda tutmalıdırlar.

Anahtar sözcükler:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.